How to manage osteoporosis after the menopause

Best Practice and Research: Clinical Rheumatology

Volumn 19, Issue 6, 2005, Pages 1007-1019

  Compston, Juliet ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Fracture; Hormone replacement therapy; Menopause; Oestrogen; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ETIDRONIC ACID; GESTAGEN; HORMONE; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE;

BONE DENSITY; BONE MINERAL; BREAST CANCER; CLIMACTERIUM; CLINICAL PROTOCOL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FRACTURE; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; LUNG EMBOLISM; MENOPAUSE; META ANALYSIS; OSTEOLYSIS; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

BONE DENSITY; FEMALE; FRACTURES, BONE; HORMONE REPLACEMENT THERAPY; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 28644434531     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2005.06.010     Document Type: Review

References (79)

1. T. Hansson & B. Roos Age changes in the bone mineral density of the lumbar spine in normal women Calcified Tissue International 38 1986 249-251
2. R.B. Mazess On aging bone loss Clinical Orthopaedics 165 1982 239-252
3. R.B. Mazess H.S. Barden M. Ettinger et al. Spine and femur density using dual-photon absorptiometry in US white women Bone and Mineral 2 1987 211-219
4. B.L. Riggs H.W. Wahner W.L. Dunn et al. Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis The Journal of Clinical Investigation 67 1981 328-335
5. B.L. Riggs H.W. Wahner L.J. Melton et al. Rates of bone loss in the appendicular and axial skeletons of women: Evidence of substantial vertebral bone loss before menopause The Journal of Clinical Investigation 77 1986 1487-1491
6. A. Rodin B. Murby M.A. Smith et al. Premenopausal bone loss in the lumbar spine and neck of femur: A study of 225 Caucasian women Bone 11 1990 1-5
7. H.K. Genant C.E. Cann B. Ettinger & S.G. Gilbert Quantitative computed tomography of vertebral spongiosa: A sensitive method for detecting early bone loss after oophorectomy Annals of Internal Medicine 97 1982 699-705
8. R. Recker J. Lappe K.M. Davies & R. Heaney Characterisation of perimenopausal bone loss: A prospective study Journal of Bone Mineral Research 15 2000 1965-1973
9. J.E. Compston Sex steroids and bone Physiological Reviews 81 2001 419-447
10. J.E. Compston K. Yamaguchi P.I. Croucher et al. The effects of gonadotrophin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis Bone 16 1995 261-267
11. V. Beral E. Banks & G. Reeves Evidence from randomised trials on the long-term effects of hormone replacement therapy Lancet 360 2002 942-944
12. D.M. Herrington & T.D. Howard From presumed benefit to potential harm - hormone therapy and heart disease The New England Journal of Medicine 349 2003 519-522
13. J.A. Kanis O. Johnell A. Oden et al. Intervention thresholds for osteoporosis Bone 31 2002 26-31
14. H.D. Nelson M. Helfand S.H. Woolf & J.D. Allen Screening for postmenopasual osteoporosis: A review of the evidence Annals of Internal Medicine 137 2002 529-541
15. J.P. Brown & R.J. Josse Clinical practice guidelnes for the diagnosis and management of osteoporosis in Canada Canadian Medical Association Journal 167 suppl 2002 1-22
16. WHO Study Group. Assessment of fracture risk and its application to postmenopausal osteoporosis. World Health Organ Tech Rep Ser NO 843 1994.
17. J.A. Kanis O. Johnell A. Oden et al. Risk of hip fracture derived from relative risks: An analysis applied to the population of Sweden Osteoporosis International 11 2000 120-127
18. J.A. Kanis O. Johnell A. Oden et al. Ten year risk of osteoporotic fracture and the effect of risk factors on screening strategies Bone 30 2002 251-258
19. J.A. Kanis Diagnosis of osteoporosis and assessment of fracture risk Lancet 359 2002 1929-1936
20. J.A. Kanis F. Borgstrom N. Zethraeus et al. Intervention thresholds for osteoporosis in the UK Bone 36 2005 22-32
21. J.A. Kanis & C-C. Glüer An update on the diagnosis and assessment of osteoporosis with densitometry Osteoporosis International 11 2000 192-202
22. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women Journal of the American Medical Association 288 2002 321-333
23. The Women's Health Initiative Steering Committee Effects of conjugated equine estrogen in postmenopausal women with hysterectomy Journal of the American Medical Association 291 2004 1701-1712
24. R. Lindsay J.M. Aitken & J.B. Anderson Long-term prevention of postmenopausal osteoporosis by oestrogen Lancet i 1976 1038-1041
25. C. Christiansen M.S. Christensen P.L. McNair et al. Prevention of early menopausal bone loss: Conducted 2-year study European Journal of Clinical Investigation 10 1980 273-279
26. B. Ettinger H.K. Genant & C.E. Cann Long-term estrogen replacement therapy prevents bone loss and fractures Annals of Internal Medicine 102 1985 319-324
27. M.E.T. Quigley P.L. Martin A.M. Burnier & P. Brooks Estrogen therapy arrests bone loss in elderly women American Journal of Obstetrics and Gynecology 156 1987 1516-1523
28. J.C. Stevenson M.P. Cust K.F. Gangar et al. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women Lancet 336 1990 265-269
29. J.W.W. Studd M. Savvas I. Fogelman et al. The relationship between plasma estradiol and the increase in bone density in women following treatment with subcutaneous hormone implants American Journal of Obstetrics and Gynecology 163 1990 1474-1479
30. T. Steiniche C. Hasling P. Charles et al. A randomised study of the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodelling in postmenopausal osteoporosis Bone 10 1989 313-320
31. S. Vedi S.J. Skingle & J.E. Compston The effects of long-term hormone replacement therapy on bone remodelling in postmenopausal women Bone 19 1996 535-539
32. S. Vedi P.I. Croucher N.J. Garrahan & J.E. Compston Effects of hormone replacement therapy on cancellous bone microstructure in postmenopausal women Bone 19 1996 69-72
33. B. Lees & J.C. Stevenson The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17β and dydrogesterone Osteoporosis International 12 2001 251-258
34. R. Lindsay J.C. Gallagher M. Kleerekoper & J.H. Pickar Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women Journal of the American Medical Association 287 2002 2668-2676
35. B. Ettinger K. Ensrud R. Wallace et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: A randomised clinical trial Obstetrics and Gynecology 104 2004 443-451
36. S. Vedi J.E. Compston P. Ballard et al. Bone remodelling and structure in postmenopausal women treated with long-term, high-dose oestrogen therapy Osteoporosis International 10 1999 52-58
37. G. Khastgir J. Studd N. Holland et al. Anabolic effect of estrogen replacement on bone in postmenopausal women with osteoporosis: histomorphometric evidence in a longitudinal study The Journal of Clinical Endocrinology and Metabolism 86 2001 289-295
38. N.S. Weiss C.L. Ure J.H. Ballard et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogens The New England Journal of Medicine 303 1980 1195-1198
39. A. Paganini-Hill R.K. Ross V.R. Gerkins et al. Menopausal estrogen therapy and hip fractures Annals of Internal Medicine 95 1981 28-31
40. K. Michaëlsson J.A. Baron B.Y. Farahmand et al. Hormone replacement therapy and risk of hip fracture: Population based case-control study British Medical Journal 316 1998 1858-1863
41. R. Lindsay D.M. Hart C. Forrest & C. Baird Prevention of spinal osteoporosis in oophorectomised women Lancet ii 1980 1151-1153
42. E.G. Lufkin H.W. Wahner W.M. O'Fallon et al. Treatment of postmenopausal osteoporosis with transdermal estrogen Annals of Internal Medicine 117 1992 1-9
43. M.H. Komulainen H. Kroger M.T. Tuppurainen et al. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial Maturitas 31 1998 45-54
44. A. Cranney G. Guyatt L. Griffith et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis Endocrine Reviews 23 2002 570-578
45. D. Torgerson & S.E.M. Bell-Syer Hormone replacement therapy and prevention of nonvertebral fractures. A meta-analysis of randomised trials Journal of the American Medical Association 285 2001 2891-2897
46. D. Torgerson & S.E.M. Bell-Syer Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials BMC Musculoskel Disorders 2 2001 7
47. J.A. Cauley D.G. Seeley K. Ensrud et al. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group Annals of Internal Medicine 122 1995 9-16
48. D.S.M.R. Grady D.B. Petitti C.S. Fox et al. Hormone replacement therapy to prevent disease and prolong life in postmenopausal women Annals of Internal Medicine 117 1992 1016-1037
49. F. Tremollieres J.M. Pouilles & C. Ribot Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women Osteoporosis International 12 2001 385-390
50. E. Sornay-Rendu P. Garnero F. Munoz et al. Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover Bone 33 2003 159-166
51. Y.Z. Bagger L.B. Tanko P. Alexandersen et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: The PERF study Bone 34 2004 728-735
52. S. Hulley D. Grady T. Bush et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Journal of the American Medical Association 280 1998 605-613
53. M.J. Stampfer G.A. Colditz W.C. Willett et al. Postmenopausal estrogen therapy and cardiovascular disease: 10 year follow-up from the Nurses Health Study The New England Journal of Medicine 325 1991 756-762
54. F. Grodstein M.J. Stampfer J.E. Manson et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease The New England Journal of Medicine 335 1996 453-461
55. K. Rödström C. Bengtsson L. Lissner & C. Björkelund Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: Prospective cohort study in Gothenburg Sweden British Medical Journal 319 1999 890-893
56. F. Grodstein T.B. Clarkson & J.E. Manson Understanding the divergent data on postmenopausal hormone therapy The New England Journal of Medicine 348 2003 645-650
57. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer Lancet 350 1997 1047-1059
58. Million Women Study Collaborators Breast cancer and hormone replacement therapy in the Million Women Study Lancet 362 2003 419-427
59. H. Jick L.E. Derby M.W. Myers et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens Lancet 348 1996 981-983
60. F. Grodstein J.J. Stampfer & S.Z. Goldhaber Prospective study of exogenous hormones and risk of pulmonary embolism Lancet 348 1996 983-987
61. R.T. Chlebowski J. Wactawski-Wende C. Ritenbaugh et al. Estrogen plus progestin and colorectal cancer in postmenopausal women The New England Journal of Medicine 350 2004 991-1004
62. P.A. Newcomb & B. Storer Postmenopausal hormone use and risk of large bowel cancer Journal of the National Cancer Institute 87 1995 1067-1071
63. F. Grodstein P.A. Newcomb & J.J. Stampfer Postmenopausal hormone therapy and the risk of colo-rectal cancer: A review and meta-analysis The American Journal of Medicine 106 1999 574-582
64. M.X. Tang D. Jacobs Y. Stern et al. Effect of oestrogen during menopause on risk and age of onset of Alzheimer's disease Lancet 348 1996 429-432
65. S.R. Rapp M.A. Espeland S.A. Shumaker et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women Journal of the American Medical Association 289 2003 2663-2672
66. J.E. Compston Pharmacological interventions for postmenopausal osteoporosis: An evidence-based approach Rheumatology 39 2000 1309-1312
67. D. Black D. Thompson S.A. Quandt L. Palermo K. Ensrud & O. Johnell Alendronate reduces risk of vertebral fracture in women with BMD T-scores above -2.5: Results from the fracture intervention trial (FIT) Journal of Bone Mineral Research 17 2002 S474
68. S.T. Harris N.B. Watts H.K. Genant et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial Journal of the American Medical Association 282 1999 1344-1352
69. J-Y. Reginster H.W. Minne O.H. Sorensen et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis Osteoporosis International 11 2000 83-91
70. M.R. McClung P. Geusens P.D. Miller et al. Effect of risedronate on the risk of hip fracture in elderly women The New England Journal of Medicine 344 2001 333-340
71. T. Storm G. Thamsborg T. Steiniche et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis The New England Journal of Medicine 322 1990 1265-1271
72. B. Ettinger D.M. Black B.H. Mitlak et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial Journal of the American Medical Association 282 1999 637-645
73. C.H. Chesnut S. Silverman K. Andriano et al. A randomised trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study The American Journal of Medicine 109 2000 267-276
74. P.J. Meunier E. Confavreux I. Tupinon et al. Prevention of early postmenopausal bone loss with cyclical etidronate therapy: A double-blind, placebo-controlled study and 1-year follow-up The Journal of Clinical Endocrinology and Metabolism 82 1997 2784-2791
75. P.D. Delmas N.H. Bjarnason B.H. Mitlak et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women The New England Journal of Medicine 337 1997 1641-1647
76. D. Hosking C.E.D. Chilvers C. Christiansen et al. Prevention of bone loss with alendronate in postmenopausal women under sixty years of age The New England Journal of Medicine 338 8 1998 485-492
77. L. Mortensen P. Charles P.J. Bekker et al. Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up The Journal of Clinical Endocrinology and Metabolism 83 1998 396-402
78. R.M. Neer C.D. Arnaud J.R. Zanchetta et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis The New England Journal of Medicine 344 2001 1434-1441
79. P.J. Meunier C. Roux E. Seeman et al. The effect of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis The New England Journal of Medicine 350 2004 459-468